 Rigel Pharmaceuticals Inc NASDAQ: RIGL shares are falling on disappointing data from the FORWARD Phase 3 trial of fostamatinib in patients with warm autoimmune hemolytic anemia wAIHA. wAIHA is an autoimmune disorder characterized by the premature destruction of healthy red blood. 